Introduction
============

Risk stratification plays an increasing role in contemporary management of patients with cardiovascular disease. Traditionally, the presence of specific clinical signs and symptoms coupled with abnormalities in cardiac‐specific measurements and estimates of end‐organ dysfunction generates an integrated view of an individual patient\'s risk profile. Recently, the broad acceptance of novel blood‐based biomarkers has emerged in the arena of risk stratification, even though the true incremental value of such measures in routine clinical practice has been challenged in population‐based studies.^[@b1]--[@b2]^

Cardiovascular health relies heavily on maintaining appropriate dietary behaviors and physical activities.^[@b3]^ The ability to determine functional capacity has relied on subjective assessment based on direct patient interviews during the history and physical examination and objectively by quantifying measures identified from standardized exercise testing. Standardized instruments to assess functional capacity and/or health status have been developed,^[@b4]--[@b5]^ but their clinical adoption has been challenged by both logistical hurdles and an emphasis on "hard" clinical end points in the determination of treatment responses. Remarkably, few studies have undertaken the prospective validation of the functional capacity measures in the prediction of future major adverse cardiac outcomes beyond all‐cause mortality alone or direct comparisons with clinically available biomarkers. Here, we sought to determine the prognostic value of estimating functional capacity using a simple self‐administered assessment tool in a contemporary stable cardiac patient population.

Methods
=======

Study Population
----------------

The Cleveland Clinic Institutional Review Board approved the study. The GeneBank study was conducted via prospective screening of patients aged ≥18 years who underwent elective coronary evaluation with coronary angiography or computed tomography between 2001 and 2007. Consecutive patients were screened and considered for enrollment without intentional exclusion. At the time of enrollment, we excluded patients who had known acute coronary syndrome within 30 days of enrollment and those who were unable to comply with or unwilling to follow study protocol. All potentially eligible patients were approached, and those who agreed to participate were provided with written informed consent.

Data Synthesis
--------------

All clinical characteristics were determined by patient self‐report and confirmed by clinical histories from Electronic Medical Record. Coronary artery disease (CAD) was defined as any clinical history of myocardial infarction (MI), percutaneous coronary intervention, or coronary artery bypass graft surgery. Peripheral artery disease (PAD) was defined as a self‐reported history of non‐CAD cardiovascular disease and/or history of or repair of aortic dissection/aneurysm. Self‐reported degree of angina was quantified by Canadian Cardiovascular Society (CCS) angina classification.^[@b6]^

Assessment of Functional Capacity: The Duke Activity Status Index Questionnaire
-------------------------------------------------------------------------------

The Duke Activity Status Index (DASI) questionnaire is a self‐assessment tool to estimate functional capacity,^[@b7]^ which includes 12 activities representative of major aspects of physical function (personal care, ambulation, household tasks, sexual function, and recreational activities). It was developed to predict an individual\'s maximal exercise capacity. A score is calculated based on weighted answers from 12 questions related to daily activities of living, for which each item is weighted by its known metabolic cost, and weights of positive terms are summed to form the individual patient DASI score. The possible scores range from 0 (all "no" answers) to 58.2 (all "yes" answers). The DASI assessment was prospectively performed in this study as a predefined assessment of signs and symptoms related to activities of daily living at the time of enrollment and was performed by study personnel in a systematic manner whereby only definitive answers were scored. Specifically, trained research personnel approached each patient shortly after informed consent to administer the DASI questionnaire. Estimated peak oxygen consumption was calculated according the original formula from Hlatky and colleagues^[@b7]^: peak Vo~2~ (in mL×kg^−1^×min^−1^)=0.43×DASI+9.6, whereas metabolic equivalent (MET) was calculated as: 1 MET=3.5 mL×kg^−1^×min^−1^ Vo~2~.

Outcome Measures
----------------

All 8987 patients were followed prospectively over the ensuing 3 years by telephone contact, mailing, and medical record review by designated research personnel independent of study investigators. All major adverse cardiovascular events (MACE), defined as death, nonfatal MI, or nonfatal stroke after enrollment, were adjudicated with source documentation. Significantly obstructive CAD was defined as any clinical history of MI, percutaneous coronary intervention, coronary artery bypass graft surgery, or angiographic evidence of CAD (≥50% stenosis) in ≥1 major coronary artery. Subsequent MI was adjudicated from source documentation with supporting evidence including elevated cardiac enzymes, significant Q‐wave definitive electrocardiographic evidence of new infarction, the presence of myocardial wall akinesis or scar on imaging, or treatment with thrombolytic agents or direct percutaneous intervention. Stroke was defined as documented loss of neurologic function caused by an ischemic event with residual symptoms continuing ≥24 hours after onset (not to include transient ischemic attacks, microvascular infarcts, or amarosis fugax).

Biomarker Analyses
------------------

Blood samples were obtained either via venipuncture (in the case of coronary computed tomography patients) or during diagnostic coronary angiographic procedure right after arterial sheath access but before any heparin administration. Blood samples were immediately processed and frozen at −80°C until analysis. The biomarker subset included 4805 patients, for whom stored samples were randomly selected to undergo biomarker testing in a central core laboratory. Specifically, high‐sensitivity C‐reactive protein (hsCRP), B‐type natriuretic peptide (BNP), creatinine, fasting lipid profile, apolipoprotein A1 (apoA1), and apolipoprotein B (apoB) were all measured in the Architect ci8200 platform (Abbott Laboratories). Myeloperoxidase (MPO) was measured by using the CardioMPO assay kit (Cleveland Heart Lab). Total leukocyte count was measured by using the ADVIA 120 Hematology System (Siemens Medical Systems).

Statistical Analysis
--------------------

We used the Student\'s *t* test or Wilcoxon--rank sum test for continuous variables and χ^2^ test for categorical variables for between‐group comparisons. Logistic regression was used to determine the association with cardiovascular phenotype. Cox proportional hazards regression was used for time‐to‐event analysis to determine hazard ratio (HR) and 95% confidence intervals (CIs) for MACE in comparing the highest with the lowest DASI quartiles for each cohort of interest. Adjustments were made for individual traditional cardiac risk factors (including age, sex, low‐density and high‐density lipoprotein cholesterol, systolic blood pressure, former or current cigarette smoking, and diabetes mellitus) to predict incident 3‐year MACE risk. The survival curve was derived using Kaplan--Meier survival analysis. A cubic spline term of DASI was fitted in the Cox model to assess how the spectrum of DASI scores related to the HR of MACE. A nomogram for MACE based on survival models was constructed (details of the nomogram construction methods are listed in Data S1 as previously published^[@b8]^) to visually display the predicted probability of a MACE event from a multivariate Cox model. Net reclassification analysis was performed to quantify improvement in models with and without DASI scores. In cutoff values for net reclassification index estimation,^[@b9]^ we used a ratio of 6:3:1 for low‐, medium‐ and high‐risk categories. Comparison between DASI score and Adult Treatment Panel III score, which estimates the 10‐year risk of developing CAD outcomes (MI or coronary death),^[@b10]^ was performed by resampling (250 bootstrap samples from the whole cohort \[N=8987\]). All data analyses, including receiver operator characteristic analyses and area under the curve (AUC) determinations, were separately recalculated at each resampling, and the AUCs calculated from the bootstrap samples were compared. All analyses were performed using R 2.15.1 software. Values of *P*\<0.05 were considered statistically significant.

Results
=======

[Table 1](#tbl01){ref-type="table"} shows the baseline characteristics of the study population, which is representative of a contemporary patient population undergoing elective diagnostic coronary angiography (see Data S2). The reasons for angiography included history of positive or indeterminate stress test (45%), evaluation for possible ischemic causes of symptoms (63%), preoperative evaluation (15%), and history of cardiomyopathy (4%). The median DASI score was 38.2 (IQR 24.2 to 50.7), which corresponded to an estimated peak oxygen consumption of 26 mL/kg per minute (IQR 20 to 31 mL/kg per minute). As expected, patients with a lower DASI score were more likely to be older and female and to have an underlying history of HF, previous MI, or PAD ([Table 1](#tbl01){ref-type="table"}). We observed the association between lower DASI score with higher likelihood of underlying CAD (quartile 4 versus quartile 1 of DASI score, unadjusted odds ratio \[OR\] 2.99, 95% CI 2.59 to 3.46, *P*\<0.01) or PAD (unadjusted OR 5.65, 95% CI 4.74 to 6.73, *P*\<0.01). After adjustment for traditional risk factors, the association remained statistically significant (CAD: adjusted OR 2.65, .95% CI 2.22 to 3.15, *P*\<0.01; PAD: adjusted OR 4.61, 95% CI 3.73 to 5.71, *P*\<0.01).

###### 

Baseline Characteristics for Whole Cohort and Across Quartiles of Duke Activity Status Index (DASI) Score

                                         Whole Cohort (n=8987)   Quartile 1 (n=2193)    Quartile 2 (n=2219)   Quartile 3 (n=1597)   Quartile 4 (n=2978)   *P* Value[\*](#tf1-1){ref-type="table-fn"}
  -------------------------------------- ----------------------- ---------------------- --------------------- --------------------- --------------------- --------------------------------------------
  DASI score                                                     \<24                   24 to 38              38 to 50              ≥51                   
  Age, y                                 64±11                   68±11                  66±11                 63±10                 59±10                 \<0.001
  Male, %                                68                      52                     65                    71                    80                    \<0.001
  Smoker, %                              66                      66                     66                    68                    65                    0.214
  Diabetes mellitus, %                   38                      51                     42                    37                    26                    \<0.001
  Hypertension, %                        74                      81                     77                    74                    65                    \<0.001
  History of CAD, %                      68                      77                     72                    66                    59                    \<0.001
  History of MI, %                       38                      47                     39                    36                    32                    \<0.001
  History of HF, %                       21                      38                     22                    16                    9                     \<0.001
  History of PAD, %                      26                      38                     32                    23                    15                    \<0.001
  History of stroke, %                   7                       12                     8                     5                     3                     \<0.001
  History of ventricular arrhythmia, %   9                       11                     10                    8                     8                     0.001
  LVEF \<50% (%)                         26                      35                     28                    24                    19                    \<0.001
  BMI, kg/m^2^                           28.7 (25.7 to 32.7)     29.4 (25.7 to 34.6)    29 (25.9 to 33.1)     28.7 (25.8 to 32.5)   28.4 (25.5 to 31.6)   \<0.001
  LDL cholesterol, mg/dL                 95 (76 to 118)          92 (73 to 114)         94 (75 to 117)        95 (76 to 118)        98 (79 to 120)        \<0.001
  HDL cholesterol, mg/dL                 38 (31 to 47)           37 (30 to 47)          38 (31 to 47)         38 (31 to 47)         38 (31 to 48)         \<0.001
  Total cholesterol, mg/dL               165 (142 to 193)        161 (138 to 191)       164 (141 to 191)      164 (143 to 193)      168 (144 to 196)      \<0.001
  Triglycerides, mg/dL                   122 (86 to 177)         129 (91 to 187)        122 (88 to 177)       122 (86 to 174)       117 (82 to 170)       \<0.001
  hsCRP, mg/L                            2.40 (1.04 to 5.91)     4.13 (1.72 to 10.26)   2.58 (1.12 to 6.03)   2.32 (1.02 to 5.22)   1.58 (0.77 to 3.77)   \<0.001
  eGFR, mL/min per 1.73 m^2^             83 (67 to 95)           72 (54 to 89)          81 (65 to 93)         86 (71 to 96)         89 (76 to 99)         \<0.001
  MPO, pmol/L                            111 (73 to 232)         127 (81 to 277)        112 (74 to 218)       108 (70 to 234)       100 (69 to 207)       \<0.001
  BNP, pg/mL                             95 (38 to 242)          176 (75 to 479)        115 (46 to 281)       83 (35 to 178)        58 (26 to 131)        \<0.001
  WBC, ×10^9^/L                          6 (5 to 8)              6 (5 to 8)             6 (5 to 8)            6 (5 to 7)            6 (5 to 7)            \<0.001
  apoA1                                  116 (103 to 132)        115 (101 to 134)       116 (103 to 132)      115 (102 to 131)      115 (104 to 131)      \<0.001
  apoB                                   81 (69 to 96)           81 (69 to 96)          82 (69 to 95)         82 (69 to 96)         81 (69 to 96)         \<0.001
  Baseline medications                                                                                                                                    
  ACE inhibitors/ARBs, %                 50                      57                     52                    52                    43                    \<0.001
  β‐Blockers, %                          62                      66                     64                    61                    57                    \<0.001
  Statin, %                              59                      59                     60                    58                    57                    0.11
  Aspirin, %                             72                      69                     72                    72                    73                    0.005

CAD indicates coronary artery disease; MI, myocardial infarction; HF, heart failure; PAD, peripheral artery disease; LVEF, left ventricular ejection fraction; BMI, body mass index; LDL, low‐density lipoprotein; HDL, high‐density lipoprotein; hsCRP, high‐sensitivity C‐reactive protein; eGFR, estimated glomerular filtration rate; MPO, myeloperoxidase; BNP, B‐type natriuretic peptide; WBC, total leukocyte count; apoA1, apolipoprotein A1; apoB, apolipoprotein B; ACE, angiotensin‐converting enzyme; ARB, angiotensin II receptor blocker.

Kruskal--Wallis test for multigroup comparisons.

The relationship between DASI score and incident cardiovascular risk is illustrated in [Figure 1](#fig01){ref-type="fig"}, in which the Kaplan--Meier analysis revealed that lower DASI score (across quartiles of DASI score as well as estimated METs) is associated with a greater risk of future development of MACE. Over a 3‐year prospective follow‐up period, there were a total of 829 deaths, 404 MIs, and 178 strokes in our study cohort. We observed that a lower DASI score was associated with a higher risk of future death, MI, or stroke (quartile 4 versus quartile 1 of DASI score, unadjusted HR 4.76, 95% CI 4.03 to 5.61, *P*\<0.01). The prognostic value of DASI score was preserved when adjusted for traditional risk factors (adjusted HR 3.77, 95% CI 3.15 to 4.51, *P*\<0.01) or even plus history of heart failure and history of PAD (adjusted HR 2.89, 95% CI 2.39 to 3.50, *P*\<0.01) and in cohorts with and without significantly obstructive CAD ([Table 2](#tbl02){ref-type="table"}). These findings were similar across previously reported METs categories^[@b11]^ ([Table 3](#tbl03){ref-type="table"}). As illustrated by the cubic spline curve, the risk for future MACE appeared to be steep and linear, with HR significantly above unity, particularly for DASI scores \<38 (or the median, [Figure 2](#fig02){ref-type="fig"}). Lower DASI scores also predicted higher future risk of MACE at 3 years regardless of age, sex, body mass index, diabetes mellitus, hypertension, lipid status, hsCRP status, or prior MI (all *P*\<0.01, [Figure 3](#fig03){ref-type="fig"}). The prognostic value of DASI score was also consistent regardless of the clinically assessed CCS angina class (see Data S3). Use of DASI score over traditional risk factors was also shown to reclassify patients (net reclassification index 15%, *P*\<0.001; integrated discrimination improvement 13%, *P*\<0.001; C‐statistics 66.5% versus 71.5%, *P*\<0.001). Direct head‐to‐head comparison also demonstrated that DASI score provided more robust prediction of future development of MACE over a 3‐year period than did the Adult Treatment Panel III score^[@b10]^ (AUC: 0.67 \[95% CI 0.66 to 0.69\] versus 0.59 \[0.57 to 0.60\], *P*\<0.001) in our study population. Combining traditional risk factors and comorbidities with DASI score, a nomogram is constructed with a point scoring system indicative of prospective risk for future MACE at 3 years ([Figure 4](#fig04){ref-type="fig"}).

![Kaplan--Meier analysis of Duke Activity Status Index (DASI) scores in predicting future risk of major adverse cardiac events in stable cardiac patients undergoing elective coronary angiography according to DASI quartiles (A) and estimated metabolic equivalents (METs, B). Ranges of DASI and METs are the same as for groups in Tables [2](#tbl02){ref-type="table"} and [3](#tbl03){ref-type="table"}. MI indicates myocardial infarction.](jah3-3-e000960-g1){#fig01}

###### 

Unadjusted and Adjusted Hazard Ratio (HR) for Major Adverse Cardiac Events at 3 Years Stratified According to Quartiles of DASI Score

                                                Quartile 4   Quartile 3                                             Quartile 2                                             Quartile 1
  --------------------------------------------- ------------ ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------
  All patients (n=8 987)                                                                                                                                                   
  Range                                         ≥51          38 to 50                                               24 to 38                                               \<24
  Unadjusted HR                                 1            1.78 (1.45 to 2.19)[\*](#tf2-1){ref-type="table-fn"}   2.54 (2.12 to 3.03)[\*](#tf2-1){ref-type="table-fn"}   4.76 (4.03 to 5.61)[\*](#tf2-1){ref-type="table-fn"}
  Adjusted HR (1)                               1            1.58 (1.29 to 1.95)[\*](#tf2-1){ref-type="table-fn"}   2.16 (1.80 to 2.59)[\*](#tf2-1){ref-type="table-fn"}   3.77 (3.15 to 4.51)[\*](#tf2-1){ref-type="table-fn"}
  Adjusted HR (2)                               1            1.53 (1.24 to 1.89)[\*](#tf2-1){ref-type="table-fn"}   1.87 (1.54 to 2.25)[\*](#tf2-1){ref-type="table-fn"}   2.89 (2.39 to 3.50)[\*](#tf2-1){ref-type="table-fn"}
  Event rate                                    187/2978     176/1597                                               341/2219                                               587/2193
  Significantly obstructive CAD (n=6 520)                                                                                                                                  
  Range                                         ≥51          37 to 51                                               23 to 37                                               \<23
  Unadjusted HR                                 1            1.63 (1.32 to 2.03)[\*](#tf2-1){ref-type="table-fn"}   2.37 (1.94 to 2.89)[\*](#tf2-1){ref-type="table-fn"}   4.21 (3.51 to 5.06)[\*](#tf2-1){ref-type="table-fn"}
  Adjusted HR (1)                               1            1.44 (1.16 to 1.78)[\*](#tf2-1){ref-type="table-fn"}   2.06 (1.68 to 2.52)[\*](#tf2-1){ref-type="table-fn"}   3.48 (2.86 to 4.25)[\*](#tf2-1){ref-type="table-fn"}
  Adjusted HR (2)                               1            1.38 (1.11 to 1.73)[\*](#tf2-1){ref-type="table-fn"}   1.76 (1.43 to 2.17)[\*](#tf2-1){ref-type="table-fn"}   2.66 (2.16 to 3.27)[\*](#tf2-1){ref-type="table-fn"}
  Event rate                                    151/1876     185/1431                                               287/1584                                               485/1629
  Not significantly obstructive CAD (n=2 467)                                                                                                                              
  Range                                         ≥58          45 to 58                                               30 to 45                                               \<30
  Unadjusted HR                                 1            1.62 (0.88 to 2.99)                                    3.32 (1.95 to 5.65)[\*](#tf2-1){ref-type="table-fn"}   5.63 (3.38 to 9.37)[\*](#tf2-1){ref-type="table-fn"}
  Adjusted HR (1)                               1            1.71 (0.91 to 3.23)                                    3.58 (2.05 to 6.28)[\*](#tf2-1){ref-type="table-fn"}   5.37 (3.06 to 9.42)[\*](#tf2-1){ref-type="table-fn"}
  Adjusted HR (2)                               1            1.76 (0.92 to 3.35)                                    3.42 (1.92 to 6.08)[\*](#tf2-1){ref-type="table-fn"}   4.66 (2.59 to 8.40)[\*](#tf2-1){ref-type="table-fn"}
  Event rate                                    18/676       24/558                                                 56/645                                                 85/588

Model 1: adjusted for traditional risk factors including age, sex, systolic blood pressure, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, smoking, and diabetes mellitus. Model 2: adjusted for Model 1 plus history of heart failure and peripheral artery disease. CAD indicates coronary artery disease; DASI, Duke Activity Status Index.

*P*\<0.01.

###### 

Unadjusted and Adjusted Hazard Ratio (HR) for Major Adverse Cardiac Events at 3 Years Stratified According to Previously Reported Metabolic Equivalents (METs) Categories^[@b11]^

  Range             9.9 METs   7.5 to 9.8 METs                                        4.8 to 7.4 METs                                        1.0 to 4.7 METs
  ----------------- ---------- ------------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------
  Unadjusted HR     1          1.88 (1.46 to 2.42)[\*](#tf3-1){ref-type="table-fn"}   3.63 (2.87 to 4.6)[\*](#tf3-1){ref-type="table-fn"}    6.86 (5.38 to 8.75)[\*](#tf3-1){ref-type="table-fn"}
  Adjusted HR (1)   1          1.63 (1.25 to 2.11)[\*](#tf3-1){ref-type="table-fn"}   2.86 (2.23 to 3.66)[\*](#tf3-1){ref-type="table-fn"}   5.21 (4.00 to 6.79)[\*](#tf3-1){ref-type="table-fn"}
  Adjusted HR (2)   1          1.64 (1.25 to 2.14)[\*](#tf3-1){ref-type="table-fn"}   2.47 (1.91 to 3.21)[\*](#tf3-1){ref-type="table-fn"}   3.97 (3.00 to 5.26)[\*](#tf3-1){ref-type="table-fn"}
  Event rate        79/1593    264/2839                                               562/3253                                               386/1302

Model 1: adjusted for traditional risk factors including age, sex, systolic blood pressure, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, and smoking, diabetes mellitus. Model 2: adjusted for model 1 plus history of heart failure and peripheral artery disease.

*P*\<0.01.

![Cubic spline curve for hazard ratios for major adverse clinical events (MACE) at 3 years with Duke Activity Status Index (DASI) scores.](jah3-3-e000960-g2){#fig02}

![Subgroup analysis of Duke Activity Status Index (DASI) scores and future risk of major adverse cardiac events (MACE) according to standard cardiac biomarkers. Hazard ratio (*x*‐axis) of 3‐year MACE similar to that presented in [Table 2](#tbl02){ref-type="table"} (quartile 4 vs quartile 1 of DASI score) but across subgroups of different biomarker cutoffs. apoA1 indicates apolipoprotein A1; apoB, apolipoprotein B; BNP, B‐type natriuretic peptide; eGFR, estimated glomerular filtration rate; HDL, high‐density lipoprotein; hsCRP, high‐sensitivity C‐reactive protein; LDL, low‐density lipoprotein; MPO, myeloperoxidase; WBC, white blood cell count.](jah3-3-e000960-g3){#fig03}

![Nomogram for estimating risk of major adverse cardiac events (MACE) incorporating Duke Activity Status Index (DASI) score with traditional risk factors. Methodology as described in Data S1. HDL indicates high‐density lipoprotein; LDL, low‐density lipoprotein; SBP, systolic blood pressure.](jah3-3-e000960-g4){#fig04}

In the subset of patients with biomarkers measured (n=4805), there were no significant differences in baseline characteristics compared with those without biomarker assessment. Lower DASI scores remained prognostically significant in both high and low levels of fasting lipid profiles, hsCRP, and BNP, as well as total leukocyte count and MPO. In fact, the predictive value of DASI score in predicting future MACE (AUC: 0.67 \[95% CI 0.66 to 0.69\]) appears to be comparable with commonly used prognostic cardiac biomarkers such as BNP (AUC: 0.68 \[95% CI 0.66 to 0.70\] or hsCRP (AUC: 0.61 \[95% CI 0.59 to 0.64\]). When hsCRP, BNP, and estimated glomerular filtration rate were all added to the multivariate model that included traditional risk factors, lower DASI score (quartile 4 versus quartile 1) still demonstrated a significant 2‐fold increased risk in future MACE at 3 years (adjusted HR 2.00, 95% CI 1.55 to 2.58, *P*\<0.01).

Discussion
==========

The key finding of this study is the strong prognostic value of functional capacity estimated by using a simple 12‐question evaluation tool in a large, contemporary cohort of stable cardiac patients undergoing coronary angiography. We observed that the functional capacity estimated with the DASI score is incremental and superior to that of traditional cardiovascular risk factors, with or without underlying heart failure. We further established the association between functional capacity estimated by DASI score and markers of inflammation and oxidative stress in a subset of patients. Taken together, our findings underscore the relative importance of objectively determining the functional capacity for purposes of risk stratification in cardiac patients.

Although the DASI questionnaire was developed over 2 decades ago, the primary focus in using this self‐assessment tool thus far has been to estimate functional capacity in the setting of preoperative evaluation or prediction of underlying ischemia.^[@b7],[@b12]--[@b13]^ While the original objective of DASI was to estimate functional capacity, the responses can also be used to assess physical limitations relevant to an individual\'s quality of life and to potentially uncover significant problems related to patients who experienced CAD, PAD, or heart failure. The importance of prognostication of DASI in our study, particularly with its strong incremental value to traditional risk factors and cardiac biomarkers, underscores the need to systematically assess how DASI score can be of clinical utility. Indeed, the findings of our study may not be limited to DASI or even to CAD patients, in that other instruments that assess daily physical activity such as the RAND Physical Limitation Scale^[@b14]^ or the Kansas City Cardiomyopathy Questionnaire for heart failure^[@b15]--[@b16]^ have also demonstrated their incremental prognostic utilities and responses to therapeutic interventions. These latter instruments aim to assess health status and have not been evaluated as to whether they correlate directly with functional capacity.^[@b17]^ Interestingly, the design of DASI queries an individual\'s self‐perception of his or her functional capacity (ie, what an individual is able to do) rather than a direct recall of prior physical activities and/or limitations. Therefore, the DASI questionnaire may potentially overestimate the actual functional capacity as illustrated in the validation studies,^[@b18]^ yet this further underscores an even greater importance for a standardized instrument such as the DASI questionnaire to estimate functional capacity when the ability to reclassify risk may be up to 15% as shown in our study.

While the prognostic value for functional capacity as determined by standardized exercise testing has been well established, the requirements of testing skills, equipment, and experience often hinder broad adoption. At the other end of the spectrum, simple grading systems such as New York Heart Association Classification and CCS angina classification have aided physicians in communicating the degrees of symptomatic severity, yet they are often subjective and imprecise. Hence, the ability for a series of questions that can be collected at the bedside (or adapted to remote monitoring devices or portals) to risk stratify patients for future MACE above and beyond established prognostic cardiac biomarkers speaks to the enduring importance of bedside evaluation of patient‐centered reporting of functional limitations in the era of biomarker testing. Our findings also highlight the limitations of any clinical or biochemical measure to adequately quantify functional limitations that may be more meaningful to patients. Based on our findings, the quest is to examine what treatment strategies (eg, the ability to detect impaired functional capacity as a target of physical training and cardiac rehabilitation) can be effectively incorporated in those patients with low DASI scores to improve their perceived or objective functional capacity and to determine whether such interventions can modify the natural history of the disease.

Few studies have directly examined the potential use of DASI to predict long‐term adverse cardiovascular risk in a broad patient population with stable cardiac disease. Indeed, the Women\'s Ischemia Syndrome Evaluation (WISE) study was one of the first studies to identify that functional impairment estimated by the DASI correlates with indeterminate exercise test results and is associated with an adverse prognosis among women with suspected myocardial ischemia.^[@b11]^ Surgical studies also illustrated the finding that poor functional capacity estimated by DASI following cardiac surgery identifies patients who are at risk for reduced long‐term survival.^[@b19]^ Of note, the relationship between DASI score and risk was linear and extended to the higher functional capacity end (higher score). Thus, those who achieved a maximum baseline DASI demonstrated better risk‐adjusted long‐term survival (HR 0.64; 95% CI 0.50 to 0.83; *P*=0.0005).^[@b19]^ Such a finding is consistent with improved overall survival conferred by improved functional capacity achieved during cardiac rehabilitation in the post cardiothoracic surgical setting.^[@b19]^ In the setting of heart failure or chronic kidney disease, the ability to assess functional status and prognosis has been demonstrated.^[@b18],[@b20]^ Recent data from a large heart failure cohort further implied that those with changes in DASI scores over 1 year demonstrated stronger association with long‐term outcomes than objective assessment (6‐minute walk distance).^[@b21]^ These findings are supportive of the ability of improving DASI score as a potential therapeutic target. Future investigations into potential benefits of using DASI scores (especially those with DASI \<38) to triage cardiac evaluation and guide therapeutic interventions, such as more in‐depth evaluation of disability, more aggressive secondary prevention strategies, more intensive cardiac rehabilitation, or closer outpatient follow‐up, are therefore warranted for this higher‐risk population.

Despite one of the largest studies conducted to date on the prognostic value of DASI and functional capacity in the cardiovascular population, our study has several limitations. The large sample size is reassuring regarding how the results can be generalized, although it may not be completely generalizable beyond the setting of coronary evaluation due to referral and ascertainment bias at the point of recruitment and study (ie, cardiac catheterization laboratory). There are also several notable limitations. First, while DASI has been validated in the past as a measure of metabolic capacity and function, there is no objective validation of functional capacity measurement in our large cohort besides angina class, and the ability to respond to the questions is required (thus excluding those that were unable to complete the questionnaires due to their underlying diseases or functional or communication limitations). We did not systematically collect baseline or interim information regarding history of atrial fibrillation and stroke in those enrolled. Second, we only have biochemical analyses on roughly half of the study cohort, although there is still adequate power to determine the incremental prognostic value of the DASI score. Third, although we have provided subgroup assessment in the non--heart failure and non‐PAD cohorts (potential confounding effect due to underlying cardiac and vascular insufficiency), we cannot exclude other reasons that affect an individual\'s functional limitations. Nevertheless, this also speaks to the power of this simple questionnaire that can depict risks that are otherwise unaccounted for, such as frailty, deconditioning, or psychosocial issues. Last, the fact that there is only a single time‐point assessment may require further studies to determine if improvement in DASI score can be associated with improvement in short‐ and long‐term prognosis as implied in the postsurgical or heart failure literature or with treatment strategies such as cardiac rehabilitation.^[@b19]^ We would also like to emphasize that the nomogram is largely derived to highlight the relative clinical contributions of DASI to the overall prognostic value when other factors of functional capacity are under consideration. All patients were used in deriving the score, and further validation of this score is warranted in an independent study population.

Conclusion
==========

The DASI, a self‐assessment tool of functional capacity, provides strong independent and incremental prognostic value for long‐term adverse clinical events that is comparable to cardiac biomarkers in stable cardiac patients undergoing coronary evaluation.

Supplementary Material
======================
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**Appendix** Data supplements S1 to S3.
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Click here for additional data file.
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